01 / ATLAS
What it is
BPC-157 is a 15-amino-acid peptide studied mainly in experimental tissue research. [1]
02 / ATLAS
How it works
Studies have investigated tendon fibroblast migration and survival, including FAK–paxillin signaling. These mechanisms were observed in experimental models. [1]
03 / ATLAS
What research shows
Preclinical research suggests effects on some repair processes. A cellular response in a laboratory does not demonstrate healing of a tendon tear in humans. [1]
04 / ATLAS
Study data
Chang et al., 2011: tests on rat tendon cells and tissue fragments examined cell migration and survival under stress. This was not a randomized therapeutic trial in patients. [1]
The study does not provide a validated clinical regimen for human use.
05 / ATLAS
Safety and observed adverse reactions
The FDA describes insufficient safety information and potential issues involving immunogenicity, impurities and substance characterization. [2]
These sources cannot establish the true frequency of adverse reactions during unsupervised use.
06 / ATLAS
Research status
Evidence for indications promoted online remains insufficient for robust therapeutic conclusions. Evaluation of a substance for compounding is not equivalent to medicine approval. [3]
07 / REFERENCES
Studies and sources
- Chang et al. · Tendons, cell migration and BPC-157 (2011) ↗Original research · preclinical
- FDA · Potential risks and safety-data gaps ↗Official assessment · United States
- FDA · BPC-157 documentation, 2026 ↗Official document · PDF